Human ferritin heavy chain (HFt) has been demonstrated to possess considerable potential for targeted delivery of drugs and diagnostic agents to cancer cells. Here, we report the development of a novel HFt-based genetic construct (HFt-MP-PAS) containing a short peptide linker (MP) between each HFt subunit and an outer shielding polypeptide sequence rich in proline (P), serine (S) and alanine (A) residues (PAS). The peptide linker contains a matrix-metalloproteinases (MMPs) cleavage site that permits the protective PAS shield to be removed by tumor-driven proteolytic cleavage within the tumor microenvironment. For the first time HFt-MP-PAS ability to deliver doxorubicin to cancer cells, subcellular localization, and therapeutic efficacy on a xenogeneic mouse model of a highly refractory to conventional chemotherapeutics type of cancer were evaluated. HFt-MP-PAS-DOXO performance was compared with the novel albumin-based drug delivery system INNO-206, currently in phase III clinical trials. The results of this work provide solid evidence indicating that the stimuli-sensitive, long-circulating HFt-MP-PAS nanocarriers described herein have the potential to be exploited in cancer therapy.

Fracasso, G., Falvo, E., Colotti, G., Fazi, F., Ingegnere, T., Amalfitano, A., Doglietto, G., Alfieri, S., Boffi, A., Morea, V., Conti, G., Tremante, E., Giacomini, P., Arcovito, A., Ceci, P., Selective delivery of doxorubicin by novel stimuli-sensitive nano-ferritins overcomes tumor refractoriness, <<JOURNAL OF CONTROLLED RELEASE>>, 2016; 239 (August): 10-18-18. [doi:10.1016/j.jconrel.2016.08.010] [http://hdl.handle.net/10807/84231]

Selective delivery of doxorubicin by novel stimuli-sensitive nano-ferritins overcomes tumor refractoriness

Tiziano; Amalfitano;Adriana; Doglietto;Giovanni; Alfieri;Patrizio; Arcovito
Penultimo
;
2016

Abstract

Human ferritin heavy chain (HFt) has been demonstrated to possess considerable potential for targeted delivery of drugs and diagnostic agents to cancer cells. Here, we report the development of a novel HFt-based genetic construct (HFt-MP-PAS) containing a short peptide linker (MP) between each HFt subunit and an outer shielding polypeptide sequence rich in proline (P), serine (S) and alanine (A) residues (PAS). The peptide linker contains a matrix-metalloproteinases (MMPs) cleavage site that permits the protective PAS shield to be removed by tumor-driven proteolytic cleavage within the tumor microenvironment. For the first time HFt-MP-PAS ability to deliver doxorubicin to cancer cells, subcellular localization, and therapeutic efficacy on a xenogeneic mouse model of a highly refractory to conventional chemotherapeutics type of cancer were evaluated. HFt-MP-PAS-DOXO performance was compared with the novel albumin-based drug delivery system INNO-206, currently in phase III clinical trials. The results of this work provide solid evidence indicating that the stimuli-sensitive, long-circulating HFt-MP-PAS nanocarriers described herein have the potential to be exploited in cancer therapy.
Inglese
Fracasso, G., Falvo, E., Colotti, G., Fazi, F., Ingegnere, T., Amalfitano, A., Doglietto, G., Alfieri, S., Boffi, A., Morea, V., Conti, G., Tremante, E., Giacomini, P., Arcovito, A., Ceci, P., Selective delivery of doxorubicin by novel stimuli-sensitive nano-ferritins overcomes tumor refractoriness, <<JOURNAL OF CONTROLLED RELEASE>>, 2016; 239 (August): 10-18-18. [doi:10.1016/j.jconrel.2016.08.010] [http://hdl.handle.net/10807/84231]
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S0168365916305120-main.pdf

non disponibili

Tipologia file ?: Versione Editoriale (PDF)
Licenza: Non specificato
Dimensione 1.11 MB
Formato Unknown
1.11 MB Unknown   Visualizza/Apri
ARCOVITO 2 Selective.pdf

accesso aperto

Tipologia file ?: Preprint (versione pre-referaggio)
Licenza: Creative commons
Dimensione 1.43 MB
Formato Adobe PDF
1.43 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/84231
Citazioni
  • ???jsp.display-item.citation.pmc??? 18
  • Scopus 52
  • ???jsp.display-item.citation.isi??? 50
social impact